Antibody

Tau Ag

Clonality: kit
Host: Mouse
Methods: ELISA
Source: Innogenetics
Cat# INNOTEST® hTau Ag
References:
Siderowf, 2010
Compta, 2010
Fagan, 2009
Buerger, 2009
Blurton-Jones, 2009
Visser, 2009
Mattsson, 2009
Shaw, 2009
Laske, 2008
Fagan, 2007
Formulation: solid-phase enzyme immunoassay, uses monoclonal AT120 for capture, HT7 and BT2 for incubation. Streptavidin detection of the antibodies.
Reactivity:
Reacts in: Human

Specificity

tau in cerebrospinal fluid

Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.

References

Paper Citations

  1. . CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010 Sep 21;75(12):1055-61. PubMed.
  2. . High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease. Neurosci Lett. 2011 Jan 7;487(2):169-73. PubMed.
  3. . Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine. 2009 Nov 1;1(8-9):371-380.
  4. . Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol. 2009 Sep;44(9):579-85. PubMed.
  5. . Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13594-9. PubMed.
  6. . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009 Jul;8(7):619-27. PubMed.
  7. . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009 Jul 22;302(4):385-93. PubMed.
  8. . Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. PubMed.
  9. . Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8 PubMed.

Further Reading

No Available Further Reading